An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer

This study is currently recruiting participants.

Study NCT00838201 Information provided by Amgen

First Received: February 5, 2009 Last Updated: November 19, 2009 History of Changes

No Study Results Posted for this Study

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	September 2012
Estimated Primary Completion Date:	April 2010 (Final data collection date for primary outcome measure)